HCV New Drugs: What's Hot in Gastroenterology - New Drug Classes Seek to Further Improve Already Favorable Outcomes in Hepatitis C

New Drug Classes Seek to Further Improve Already Favorable Outcomes in Hepatitis C
William F. Balistreri, MD
January 24, 2017
Editor's Note: Several major themes related to hepatitis C virus (HCV) emerged at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases, held November 11-15, 2016, in Boston, Massachusetts. With the success of direct-acting antiviral (DAA) regimens, presentations focused on new drugs and ways to integrate existing and upcoming agents into treatment strategies. In addition, new data on the management of patients with HCV infection during the peri-transplant period, as well as the impact of DAAs on recurrent infection after transplantation, were presented. Of special importance was a discussion on the potential reactivation of hepatitis B virus (HBV) infection during the DAA treatment of HCV infection.

Article available at Medscape, free registration required.

Index

Introduction

Glecaprevir/Pibrentasvir

Noncirrhotic Patients with Chronic HCV Genotypes 1 to 6 Infection

Chronic HCV Genotype 1 to 6 Infection and Renal Impairment

HCV Genotype 3 Infection With Previous Treatment Experience and/or Cirrhosis

Sofosbuvir/Velpatasvir/Voxilaprevir

DAA-Naive HCV Genotypes 1 to 6

Chronic HCV Genotype 1 to 6 Infection and Renal Impairment

HCV Genotype 3 Infection With Previous Treatment Experience and/or Cirrhosis

Grazoprevir/Elbasvir/Ruzasvir/MK3682

HCV Genotype 3 With Cirrhosis

Chronic HCV Genotype 1 Infection; Previously Failed DAA Regimen